3 completed, 1 enrolling by invitation. 3 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 2, Enrolling by invitation 1 |
| Not applicable | 1 | Completed 1 |
Follow Accupril: new trials by email Literature Review of Accupril trials Research Report on Accupril
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery ACEI continuation, ACEI omission - Hypotension on Induction | Phase 4 | Completed | University of Nebraska | 291 | 2015-06-01 | 2023-09-25 |
| Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF Aggressive Blood Pressure control - Atrial Fibrillation | Phase 4 | Completed | Nova Scotia Health Authority | 184 | 2009-12-01 | 2017-06-20 |
| Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension Quinapril (Accupril) plus Alpha Lipoic Acid, accupril, placebo, accupril, alpha lipoic acid - Diabetes, Hypertension | Not applicable | Completed | InVasc Therapeutics, Inc. | 23 | 2008-07-01 | 2011-05-05 |
Albuminuria (1) · Atrial Fibrillation (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Hyperkalemia (1) · Hypertension (1) · Renal Insufficiency, Chronic (1)
Baylor Research Institute (1) · InVasc Therapeutics, Inc. (1) · Nova Scotia Health Authority (1) · University of Nebraska (1)
United States (3) · Canada (1)
Jason F Shiffermiller, MD, MPH (1) · Ratika Parkash, MD MSc (1) · Syed T. Rahman, MD (1)